Versartis, Inc. is an endocrine-focused biopharmaceutical company developing long-acting therapeutic proteins for the treatment of endocrine disorders. The Company is initially developing VRS-317, its novel long-acting recombinant human growth hormone, for the treatment of pediatric growth hormone deficiency. VRS-317 is intended to reduce the burden of daily injection therapy by requiring significantly fewer injections, potentially improving compliance and yielding better treatment outcomes. The Company has recently completed a Phase 2 clinical study of VRS-317 in pediatric growth hormone deficient patients. VRS-317 is a fusion protein consisting of rhGH and a proprietary half-life extension technology known as XTEN, which is in-licensed from Amunix Operating, Inc. Amunix has granted Versartis an exclusive license under its patents and know-how related to the XTEN technology to develop and commercialize up to four licensed products, including VRS-317. Versartis was founded in December 2008 and is headquartered in Menlo Park, California, USA.

Publications show all

Versartis has published 2 articles.

Clinical Trials show all

2Phase 22Phase 2/Phase 31Phase 11Phase 1/Phase 21Phase 3

SEC Filings show all

8-K4210-Q9D710-K2S-11

Private Funding Events

DateOfferedSoldType
2014-02-20$54,999,991$54,999,991Equity
2014-02-19$10,000,000$10,000,000Equity
2013-10-11$9,999,999$9,999,999Equity
2013-07-22$12,499,999$12,499,999Equity
2013-01-28$20,499,999$7,999,999Equity
2013-01-28$4,587,998$4,587,998Equity
2011-03-09$21,107,360$14,419,861Equity

Key Executives

  • Jeffrey Cleland
    Executive Officer, Director
  • Willem Stemmer
    Director
  • Kevin Johnson
    Director
  • Srinivas Akkaraju
    Director
  • Shahzad Malik
    Director
  • Edmon Jennings
    Director
  • Anthony Sun
    Director
  • Volker Schellenberger
    Director
  • Michael Dybbs
    Director
  • Francesco de Rubertis
    Director
  • Joshua Brumm
    Executive Officer
  • Paul Westberg
    Executive Officer
  • Jay Shepard
    Director